Decision support model for pharmaceutical policy making and evaluation of implemented tools

Summarise with VIRAT
Authors: Foteini Theiakou, Φωτεινή Θειακού
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study introduces an innovative mathematical framework designed to quantify the societal cost associated with delays in the reimbursement and distribution of novel medicines. By integrating key public health and economic indicators—namely Years of Life Lost (YLL), Years of Potential Productive Life Lost (YPPLL), and Cost of Productivity Loss (CPL)—the proposed model provides a comprehensive assessment of the health, social, and economic consequences of delayed access to innovative therapies. The findings underscore the critical importance of timely pharmaceutical policy-making, particularly for medicines with high and well-documented clinical value. Delays in access not only reduce the therapeutic benefits available to patients but also amplify broader societal costs through increased premature mortality, diminished workforce participation, and heightened economic burden. The framework highlights that even relatively short delays may lead to disproportionately large losses in population health and productivity, emphasizing the need for differentiated policy approaches based on the clinical value of therapies. By adopting a broader societal perspective, the model supports a more balanced evaluation of pharmaceutical policy decisions, facilitating the trade-off between rapid patient access to innovation and the sustainability of healthcare expenditure. Furthermore, the framework functions as a decision-support tool for policymakers, enabling ex ante and ex post assessment of the societal and economic impact of reimbursement delays using data-driven methods. The study also highlights the pivotal role of data quality, completeness, and governance in ensuring reliable estimations of health and economic outcomes. Incomplete, inconsistent, or non-representative data may lead to biased assessments, suboptimal policy decisions, and inequities in access to healthcare. Overall, the proposed framework contributes to the advancement of value-based pharmaceutical policy by integratingreal-world data and mathematical modeling to maximize the societal benefits of medical innovation while safeguarding the long-term viability of healthcare systems.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Health Systems Economic Evaluations Quality of Life Global Health Care Issues

Publication details

Journal / source
National Archive of Doctoral Theses (National Documentation Center (Greece))
Publication date
1 January 2026
Language
EL
Document type
Thesis